第二代AURKA向PROTACs:结构优化,以在神经母细胞瘤中进行体内退化
Simon Krols1,2, Muhammad Rishfi3,2, Fien Martens3,2
1Laboratory of Medicinal Chemistry, Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.
Journal of medicinal chemistry
|November 18, 2025
概括
新的PROTACs,SK4454和SK5527,在神经母细胞瘤模型中有效降解极光激酶A (AURKA). 这些优化的化合物显示出改善的药理动力学,解决了早期版本潜在癌症治疗的局限性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 极光激酶A (AURKA) 是神经母细胞瘤中一个关键的致癌驱动因素和治疗点.
- 阿尔卡在线粒分裂和MYCN蛋白的稳定性中起着至关重要的作用,这使得它对神经母细胞瘤的进展至关重要.
- 上一个AURKA降解剂SK2188表现出强烈的活性,但其药物动力学性能不佳.
研究的目的:
- 优化AURKA降解剂的化学结构,以改善药理动力学特征.
- 开发新型的蛋白质溶解向嵌合体 (PROTACs),以增强类似药物的特性,用于神经母细胞瘤治疗.
- 研究限制AURKA降解剂体内功效的机制.
主要方法:
- 结构-活性关系 (SAR) 研究涉及链接器修饰和替代带结合.
- 开发和描述两个优化的 PROTAC:SK4454和SK5527.
- 在体内药理动力学研究和在神经母细胞瘤异种移植小鼠模型中的疗效评估.
- 调查多药耐药蛋白1 (MDR1) 介导的外流作为PROTAC功效的限制因素.
主要成果:
- SK4454和SK5527显示了AURKA的快速,选择性和强大的降解.
- 与SK2188.8.相比,优化的PROTACs表现出明显改善的药理动力学特性.
- 单次静脉注射SK4454或SK5527在神经母细胞瘤异种移植模型中有效降低了体内AURKA水平.
- 通过MDR1介导的排泄被确定为一个关键的机制,有助于限制PROTAC在体外功效.
结论:
- SK4454和SK5527代表了先进的AURKA降解剂,具有增强的药物动力学特征,适合进一步的临床前开发.
- 这些优化的PROTACs有望成为神经母细胞瘤的新型治疗剂.
- 了解MDR1介导的流量对于设计更有效的基于PROTAC的癌症疗法至关重要.
更多相关视频
06:29Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
Published on: July 30, 2020
3.4K
08:37Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
Published on: December 22, 2020
4.2K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:26Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K